Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance

The Journal of Dermatology
Naoya YamazakiAkira Komoto

Abstract

Treatment with immune checkpoint inhibitors has improved prognosis among patients with cutaneous melanoma, but there are still unmet medical needs in Japan, especially for mucosal melanoma and acral lentiginous melanoma (ALM) subtypes. Ipilimumab, a fully human monoclonal antibody that specifically blocks cytotoxic T-lymphocyte-associated antigen 4 and potentiates antitumor T-cell response, was approved in Japan in 2015 for the treatment of radically unresectable malignant melanoma. This postmarketing surveillance (prospective, non-interventional, multicenter, observational study) evaluated the safety (occurrence of adverse drug reactions [ADR]) and efficacy (overall survival [OS]) of ipilimumab in a real-world setting in Japan. All patients with radically unresectable malignant melanoma undergoing treatment with ipilimumab in Japan during the registration period between August 2015 and February 2017 were enrolled. In total, 547 patients were analyzed; 67.5% were 60 years old or more, 85.7% had an Eastern Cooperative Oncology Group performance status of 0-1, 50.3% had melanoma of the skin (mainly of the ALM subtype) and 73.5% had negative BRAF mutation status. Most patients had experienced recurrence and received multiple treat...Continue Reading

References

Mar 1, 2008·International Journal of Clinical Oncology·Kazuyuki IshiharaUNKNOWN Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Aug 11, 2012·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Shinsaku Kumano
Jun 19, 2013·Annals of the New York Academy of Sciences·Jedd D WolchokAlan J Korman
Feb 4, 2014·Journal of the American Academy of Dermatology·Oma N AgbaiHenry W Lim
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 28, 2015·Cancer Chemotherapy and Pharmacology·N YamazakiT Tokudome
Jan 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra P D'AngeloJedd D Wolchok
Jun 14, 2017·Melanoma Research·Taro TomizukaTakahiro Higashi
Jan 2, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Koichi SatoNobuyuki Yamamoto
Nov 18, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kenjiro NamikawaNaoya Yamazaki
Jan 25, 2019·Current Treatment Options in Oncology·Kenjiro Namikawa, Naoya Yamazaki
Sep 19, 2019·The Journal of Dermatology·Arata TsutsumidaYoshio Kiyohara
Sep 29, 2019·The New England Journal of Medicine·James LarkinJedd D Wolchok

❮ Previous
Next ❯

Citations

Oct 2, 2020·Journal of Medical Economics·Victoria Federico PalyJames Harrison
Dec 22, 2020·Frontiers in Oncology·Qingyue ZhengShu Zhang
Nov 4, 2020·Japanese Journal of Clinical Oncology·Junji Kato, Hisashi Uhara
Mar 22, 2021·Pharmacology Research & Perspectives·Etienne ChatelutDirk Jan A R Moes
Aug 28, 2021·International Journal of Cancer. Journal International Du Cancer·Elin AamdalTormod K Guren

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Clinical Trials Mentioned

NCT02717364

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.